



Figure 3.31. Compounds from different chemical classes of ACE inhibitors used in active-site analysis. Used with permission (397).

2. The compound must be capable of **assum-**ing a conformation that will present the pharmacophoric or binding-site pattern complementary to that of the receptor.
3. The compound must not compete with the receptor for space while presenting the pharmacophoric or binding-site pattern.